Maximizing Investigators' Research Award (MIRA) (R35 - Clinical Trial Optional)
Grant Opportunity Analysis
The National Institutes of Health (NIH) is offering the Maximizing Investigators' Research Award (MIRA) (R35 - Clinical Trial Optional) to provide stable and flexible funding support for individual investigators aligned with the scientific mission of the National Institute of General Medical Sciences (NIGMS). This grant aims to enhance funding stability, foster innovative research projects, and reduce administrative burdens, allowing researchers to focus more on their scientific endeavors and mentorship of junior scientists. Eligible applicants include NIGMS-funded investigators and New Investigators, with specific guidelines for Early-Stage Investigators to apply through a separate notice of funding opportunity (NOFO). The application deadline is May 26, 2028, and interested parties can reach out to NIGMS at NIGMS_EINIMIRA@nigms.nih.gov for further information. The typical budget for New Investigator MIRA grants is set at $275,000 annually in direct costs.
Eligible Applicants
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/Foreign CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. This new requirement was effective, May 1, 2025.Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.